Horst Olschewski

List of Publications by Year
in descending order

302 papers	28,873 citations	7568 77 h-index	5539 163 g-index
346 all docs	346 docs citations	346 times ranked	16318 citing authors

#	Article	IF	Citations
1	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D34-D41.	2.8	2,865
2	Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine, 2002, 347, 322-329.	27.0	1,626
3	Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S55-S66.	2.8	984
4	Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3010-3019.	1.6	967
5	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	2.2	903
6	Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. European Respiratory Journal, 2009, 34, 888-894.	6.7	853
7	Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S40-S47.	2.8	819
8	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet, The, 2002, 360, 895-900.	13.7	720
9	Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. Circulation, 2006, 114, 1482-1489.	1.6	606
10	Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 566-570.	5.6	574
11	Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 55, 1915-1922.	2.8	484
12	Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension. Annals of Internal Medicine, 2002, 136, 515.	3.9	446
13	Ambrisentan Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 529-535.	2.8	441
14	Pulmonary hypertension in chronic lung disease and hypoxia. European Respiratory Journal, 2019, 53, 1801914.	6.7	428
15	Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 600-607.	5.6	369
16	Mutations of the TGF-Î² type II receptorBMPR2 in pulmonary arterial hypertension. Human Mutation, 2006, 27, 121-132.	2.5	368
17	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. Journal of the American College of Cardiology, 2003, 42, 158-164.	2.8	359
18	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S85-S96.	2.8	353

#	Article	IF	Citations
19	Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension. Annals of Internal Medicine, 1996, 124, 820.	3.9	347
20	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1171-1177.	5.6	331
21	Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 991-996.	5.6	323
22	Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. Journal of Medical Genetics, 2003, 40, 865-871.	3.2	309
23	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. Journal of the American College of Cardiology, 2000, 35, 176-182.	2.8	296
24	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nature Communications, 2018, 9, 1416.	12.8	279
25	Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp. Annals of Internal Medicine, 2004, 141, 169.	3.9	271
26	Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1139-1141.	5.6	265
27	Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy. Thorax, 2000, 55, 1046-1051.	5.6	254
28	Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal, 2008, 31, 891-901.	6.7	253
29	Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene. Circulation, 2000, 102, 1145-1150.	1.6	235
30	Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial. Annals of Internal Medicine, 2000, 132, 435.	3.9	229
31	Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, 1971-1981.	2.8	227
32	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. European Respiratory Journal, 2017, 50, 1700578.	6.7	222
33	Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells. Circulation Research, 2006, 98, 1072-1080.	4.5	207
34	Magnetic Resonanceâ€“Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial Pressure. Circulation: Cardiovascular Imaging, 2008, 1, 23-30.	2.6	205
35	Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Circulation, 2009, 119, 1747-1757.	1.6	205
36	Sildenafil treatment for portopulmonary hypertension. European Respiratory Journal, 2006, 28, 563-567.	6.7	199

#	Article	IF	Citations
37	Pulmonary vascular resistances during exercise in normal subjects: a systematic review. European Respiratory Journal, 2012, 39, 319-328.	6.7	194
38	Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension. Circulation, 2013, 128, 2005-2015.	1.6	193
39	Prostanoid therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 43, S56-S61.	2.8	184
40	Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities. Chest, 2009, 135, 122-129.	0.8	167
41	Abnormalities of Gastric Mucosal Oxygenation in Septic Shock. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 1586-1592.	5.6	157
42	Reading Pulmonary Vascular Pressure Tracings. How to Handle the Problems of Zero Leveling and Respiratory Swings. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 252-257.	5.6	156
43	PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene, 2015, 34, 1044-1050.	5.9	154
44	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 341-344.	5.6	152
45	Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension. Respiration, 2011, 81, 394-401.	2.6	151
46	Gluconeogenesis in cancer cells â€“ Repurposing of a starvation-induced metabolic pathway?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 24-36.	7.4	146
47	Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 509-516.	5.6	145
48	Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 881-886.	5.6	141
49	Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertensionâ€“Targeted Therapy. Circulation: Cardiovascular Imaging, 2014, 7, 107-114.	2.6	139
50	Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 873-884.	10.7	139
51	Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension. Journal of the American College of Cardiology, 2006, 48, 1672-1681.	2.8	135
52	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology, 2004, 44, 1488-1496.	2.8	134
53	Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension. Radiology, 2015, 275, 71-79.	7.3	129
54	Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension. Chest, 2003, 124, 1294-1304.	0.8	124

#	Article	IF	Citations
55	Zero reference level for right heart catheterisation. European Respiratory Journal, 2013, 42, 1586-1594.	6.7	124
56	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
57	Prostacyclin and its analogues in the treatment of pulmonary hypertension. , 2004, 102, 139-153.		119
58	Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2006, 48, 1433-1437.	2.8	115
59	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	5.6	111
60	Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling. Journal of Applied Physiology, 1988, 64, 803-811.	2.5	110
61	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
62	Peripheral airway obstruction in primary pulmonary hypertension. Thorax, 2002, 57, 473-476.	5.6	109
63	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2016, 4, 445-453.	10.7	108
64	Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. European Respiratory Journal, 2013, 41, 85-95.	6.7	104
65	Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 98-111.	5.6	101
66	Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. European Respiratory Journal, 2001, 17, 14-19.	6.7	100
67	Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation, 2011, 30, 1327-1333.	0.6	98
68	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	1.7	96
69	Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. European Respiratory Journal, 2014, 44, 951-962.	6.7	94
70	The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1701214.	6.7	91
71	Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension. Chest, 2013, 143, 315-323.	0.8	90
72	Pulmonary Hypertension. Deutsches Ärzteblatt International, 2017, 114, 73-84.	0.9	87

#	Article	IF	Citations
73	Between inflammation and thrombosis: endothelial cells in COVID-19. European Respiratory Journal, 2021, 58, 2100377.	6.7	86
74	Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease. Chest, 2010, 138, 270-278.	0.8	83
75	Biomarkers in Pulmonary Hypertension. Chest, 2013, 144, 274-283.	0.8	83
76	Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients. PLoS ONE, 2014, 9, e87515.	2.5	83
77	Physiologic basis for the treatment of pulmonary hypertension. Translational Research, 2001, 138, 287-297.	2.3	81
78	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 575-585.	5.6	80
79	Nocturnal periodic breathing in primary pulmonary hypertension. European Respiratory Journal, 2002, 19, 658-663.	6.7	79
80	Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents. British Journal of Pharmacology, 2005, 146, 826-833.	5.4	73
81	Inhaled iloprost is a potent acute pulmonary vasodilator in HIVâ€related severe pulmonary hypertension. European Respiratory Journal, 2004, 23, 321-326.	6.7	72
82	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine, 2010, 104, 731-740.	2.9	72
83	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Critical Care Medicine, 2002, 30, 2489-2492.	0.9	69
84	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	5.6	68
85	Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension. Journal of Medical Genetics, 2004, 41, e127-e127.	3.2	65
86	Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis and Rheumatism, 2012, 64, 1257-1262.	6.7	65
87	Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L1002-L1013.	2.9	65
88	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 824-832.	2.6	64
89	Characterization of Patients With Borderline Pulmonary Arterial Pressure. Chest, 2014, 146, 1486-1493.	0.8	64
90	Targeting TMEM16A to reverse vasoconstriction and remodelling inÂidiopathic pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1800965.	6.7	62

#	Article	IF	Citations
91	Evaluation of Elevated Mean Pulmonary Arterial Pressure Based on Magnetic Resonance 4D Velocity Mapping: Comparison of Visualization Techniques. PLoS ONE, 2013, 8, e82212.	2.5	61
92	Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. European Respiratory Journal, 2012, 39, 119-124.	6.7	60
93	Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1Î± destabilization. Molecular Cancer, 2015, 14, 4.	19.2	60
94	Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Medicine, 1998, 24, 631-634.	8.2	59
95	Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respiratory Research, 2011, 12, 99.	3.6	59
96	Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart, 2017, 103, 774-782.	2.9	59
97	Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 476-483.	2.9	58
98	Cellular pathophysiology and therapy of pulmonary hypertension. Translational Research, 2001, 138, 367-377.	2.3	57
99	Meprin Î², a novel mediator of vascular remodelling underlying pulmonary hypertension. Journal of Pathology, 2014, 233, 7-17.	4.5	57
100	Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension. Journal of the American College of Cardiology, 2001, 38, 1130-1136.	2.8	56
101	Diagnostic and Therapeutic Gaps inÂPatients With HeartÂFailure and ChronicÂObstructive PulmonaryÂDisease. JACC: Heart Failure, 2019, 7, 823-833.	4.1	55
102	Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction. PLoS ONE, 2012, 7, e43793.	2.5	55
103	Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension. Cerebrovascular Diseases, 2006, 21, 194-200.	1.7	54
104	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800564.	6.7	54
105	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 2020, 12, 2319.	3.7	52
106	Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model â€“ role of tumor stroma cells. BMC Cancer, 2014, 14, 40.	2.6	51
107	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	2.2	51
108	Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer. Molecular Oncology, 2020, 14, 2853-2867.	4.6	51

#	Article	IF	Citations
109	Pulmonary hypertension in chronic obstructive pulmonary disease. British Journal of Pharmacology, 2021, 178, 132-151.	5.4	51
110	Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Letters, 2011, 308, 134-143.	7.2	48
111	Multi-channel lung sound classification with convolutional recurrent neural networks. Computers in Biology and Medicine, 2020, 122, 103831.	7.0	48
112	Increased neutrophil mediator release in patients with pulmonary hypertension â€“ suppression by inhaled iloprost. Thrombosis and Haemostasis, 2003, 90, 1141-1149.	3.4	47
113	MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Letters, 2020, 469, 266-276.	7.2	47
114	Elevated pulmonary vascular resistance predicts mortality in COPD patients. European Respiratory Journal, 2021, 58, 2100944.	6.7	47
115	Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology, 2011, 154, S20-S33.	1.7	46
116	Peroxisome Proliferatorâ€“Activated Receptorâ€“Î²/Î´, the Acute Signaling Factor in Prostacyclin-Induced Pulmonary Vasodilation. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 372-379.	2.9	44
117	Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics. European Radiology, 2017, 27, 157-166.	4.5	44
118	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulmonary Pharmacology and Therapeutics, 2009, 22, 50-56.	2.6	43
119	MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget, 2017, 8, 115754-115773.	1.8	43
120	Network Analysis to Risk Stratify Patients With Exercise Intolerance. Circulation Research, 2018, 122, 864-876.	4.5	42
121	The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 6225-6230.	7.1	42
122	The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension. Respiration, 2008, 76, 458-470.	2.6	40
123	Long nonâ€coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1â€AS1. Journal of Pathology, 2019, 247, 357-370.	4.5	40
124	TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers. PLoS ONE, 2016, 11, e0157453.	2.5	39
125	Advantage of buffered solutions or automated capnometry in air-filled balloons for use in gastric tonometry. Intensive Care Medicine, 1997, 23, 423-427.	8.2	36
126	Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca2+-dependent induction of oxidative stress. Free Radical Biology and Medicine, 2012, 52, 1786-1795.	2.9	35

#	Article	IF	Citations
127	Ion channels and transporters as therapeutic targets in the pulmonary circulation. , 2014, 144, 349-368.		35
128	Automated integer programming based separation of arteries and veins from thoracic CT images. Medical Image Analysis, 2016, 34, 109-122.	11.6	35
129	Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions. Matrix Biology, 2018, 68-69, 507-521.	3.6	35
130	Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue. Journal of Allergy and Clinical Immunology, 2020, 145, 818-833.e11.	2.9	35
131	Inhaled iloprost for the treatment of pulmonary hypertension. European Respiratory Review, 2009, 18, 29-34.	7.1	34
132	Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 63-68.	1.7	34
133	Disconnect between Fibrotic Response and Right Ventricular Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1550-1560.	5.6	34
134	Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 149.	3.9	33
135	HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?. Journal of Heart and Lung Transplantation, 2012, 31, 1109-1114.	0.6	33
136	Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography. Journal of the American Society of Echocardiography, 2015, 28, 828-843.	2.8	33
137	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respiratory Physiology and Neurobiology, 2007, 159, 196-201.	1.6	32
138	Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries. International Journal of Nanomedicine, 2014, 9, 3249.	6.7	32
139	Resident cell lineages are preserved in pulmonary vascular remodeling. Journal of Pathology, 2018, 244, 485-498.	4.5	32
140	Biomarkers for Pulmonary Vascular Remodeling in Systemic Sclerosis: A Pathophysiological Approach. Frontiers in Physiology, 2018, 9, 587.	2.8	32
141	Importance of kynurenine in pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L741-L751.	2.9	31
142	IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. European Respiratory Journal, 2019, 54, 1900154.	6.7	31
143	Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 1076-1085.	4.3	30
144	Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31. Journal of the American College of Cardiology, 2003, 41, 2237-2244.	2.8	29

#	Article	IF	Citations
145	Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer, 2009, 65, 98-104.	2.0	29
146	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
147	Basement Membrane Remodeling Controls Endothelial Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 104-117.	2.9	29
148	Severe Pulmonary Hypertension in COPD. Chest, 2022, 162, 202-212.	0.8	29
149	Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes. British Journal of Anaesthesia, 1999, 82, 435-438.	3.4	28
150	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. European Respiratory Journal, 2017, 50, 1601708.	6.7	28
151	ARIES-1: A PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AMBRISENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2006, 130, 121S.	0.8	27
152	Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stemâ€Cell Transplantation. Journal of Infectious Diseases, 2008, 198, 150-153.	4.0	27
153	Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS ONE, 2016, 11, e0168706.	2.5	27
154	Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. European Respiratory Journal, 2022, 60, 2103181.	6.7	27
155	Aspergillus oryzae Peritonitis in CAPD: Case Report and Review of the Literature. American Journal of Kidney Diseases, 2007, 49, 701-704.	1.9	26
156	Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension. European Respiratory Journal, 2016, 48, 1127-1136.	6.7	26
157	Crackle and Breathing Phase Detection in Lung Sounds with Deep Bidirectional Gated Recurrent Neural Networks. , 2018, 2018, 356-359.		26
158	Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension. Chest, 2005, 128, 630S-633S.	0.8	25
159	Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study. European Radiology, 2014, 24, 668-676.	4.5	25
160	Proposed new definition of exercise pulmonary hypertension decreases false-positive cases. European Respiratory Journal, 2016, 47, 1270-1273.	6.7	25
161	Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders. European Respiratory Journal, 2002, 19, 664-671.	6.7	24
162	Delayed Processing of Blood Samples Influences Time to Positivity of Blood Cultures and Results of Gram Stain-Acridine Orange Leukocyte Cytospin Test. Journal of Clinical Microbiology, 2007, 45, 2691-2694.	3.9	24

#	Article	IF	Citations
163	Portopulmonary hypertension: short review. European Journal of Gastroenterology and Hepatology, 2010, 22, 385-390.	1.6	24
164	Intimal Sarcoma of the Pulmonary Valve. Annals of Thoracic Surgery, 2010, 89, e25-e27.	1.3	24
165	Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis. BMC Pulmonary Medicine, 2019, 19, 230.	2.0	24
166	Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. British Journal of Pharmacology, 2007, 151, 779-786.	5.4	23
167	Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension. Frontiers in Physiology, 2018, 9, 537.	2.8	23
168	MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension. European Radiology, 2021, 31, 1883-1893.	4.5	23
169	Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertensionã€€â€“ Insights From the IBUKI and AIR Studies â€“. Circulation Journal, 2016, 80, 835-842.	1.6	22
170	Oncogene addiction and tumor mutational burden in nonâ€smallâ€cell lung cancer: Clinical significance and limitations. Thoracic Cancer, 2020, 11, 205-215.	1.9	22
171	Severe Microcirculatory Abnormalities Elicited byE. coli Hemolysin in the Rabbit Ileum Mucosa. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1171-1178.	5.6	21
172	Impairment of the NKTâ€“STAT1â€“CXCL9 Axis Contributes to Vessel Fibrosis in Pulmonary Hypertension Caused by Lung Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 981-998.	5.6	21
173	Reply: Reading of Pulmonary Artery Pressure Tracings: The Best Compromise of Accuracy and Clinical Pertinence. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1198-1199.	5.6	20
174	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 505-513.	1.7	20
175	Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. Chest, 2021, 159, 781-790.	0.8	20
176	Cardiac responses to the Valsalva manoeuvre in different body positions. European Journal of Applied Physiology and Occupational Physiology, 1990, 61, 20-25.	1.2	19
177	Aerosolized Vasodilators in Pulmonary Hypertension. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 117-122.	1.2	19
178	Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure. European Respiratory Journal, 2003, 22, 342-347.	6.7	19
179	Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox. European Respiratory Journal, 2017, 50, 1601651.	6.7	19
180	TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1Î±. Lung Cancer, 2017, 111, 15-22.	2.0	19

#	Article	IF	Citations
181	Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40. Orphanet Journal of Rare Diseases, 2006, 1, 44.	2.7	18
182	CD133⁺ cells in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 459-469.	6.7	18
183	Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico. Infection, 2008, 36, 282-284.	4.7	17
184	Quantitative CTâ€derived vessel metrics in idiopathic pulmonary fibrosis: A structureâ€“function study. Respirology, 2019, 24, 445-452.	2.3	17
185	Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020). Wiener Klinische Wochenschrift, 2020, 132, 365-386.	1.9	17
186	Matwo-CapsNet: A Multi-label Semantic Segmentation Capsules Network. Lecture Notes in Computer Science, 2019, , 664-672.	1.3	17
187	CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis. Respiratory Research, 2020, 21, 167.	3.6	16
188	Combination Therapy in Pulmonary Arterial Hypertensionâ€”Targeting the Nitric Oxide and Prostacyclin Pathways. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 107424842110065.	2.0	16
189	Phospholipid dynamics in ex vivo lung cancer and normal lung explants. Experimental and Molecular Medicine, 2021, 53, 81-90.	7.7	16
190	Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells. Atherosclerosis, 2013, 230, 406-413.	0.8	15
191	Basic Electrical Properties ofIn situEndothelial Cells of Small Pulmonary Arteries during Postnatal Development. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 285-290.	2.9	14
192	Serotonin Transporter Gene Polymorphism in a Cohort of German Patients With Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. Chest, 2005, 128, 619S.	0.8	14
193	Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria â€“ Results from the CLARA Project . International Journal of COPD, 2020, Volume 15, 1655-1663.	2.3	14
194	Endothelial Dysfunction Following Enhanced TMEM16A Activity in Human Pulmonary Arteries. Cells, 2020, 9, 1984.	4.1	14
195	Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation. Chest, 2004, 125, 344-347.	0.8	13
196	Healthy Lung Vessel Morphology Derived From Thoracic Computed Tomography. Frontiers in Physiology, 2018, 9, 346.	2.8	13
197	Dysbalance of <scp>ACE2</scp> levels â€“ a possible cause for severe <scp>COVID</scp>â€19 outcome in <scp>COPD</scp>. Journal of Pathology: Clinical Research, 2021, 7, 446-458.	3.0	13
198	Determination of cardiac output with dynamic contrast-enhanced computed tomography. International Journal of Cardiovascular Imaging, 2013, 29, 1871-1878.	1.5	12

#	Article	IF	Citations
199	Double-Stranded RNA Attenuates the Barrier Function of Human Pulmonary Artery Endothelial Cells. PLoS ONE, 2013, 8, e63776.	2.5	12
200	The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease. Diagnostics, 2021, 11, 311.	2.6	12
201	Are anticoagulants still indicated in pulmonary arterial hypertension?. Pulmonary Circulation, 2018, 8, 1-5.	1.7	11
202	Mildly increased pulmonary arterial pressure: a new disease entity or just a marker of poor prognosis?. European Journal of Heart Failure, 2019, 21, 1057-1061.	7.1	11
203	PCK2 opposes mitochondrial respiration and maintains the redox balance in starved lung cancer cells. Free Radical Biology and Medicine, 2021, 176, 34-45.	2.9	11
204	Gluconeogenesis in cancer: Door wide open. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4394.	7.1	10
205	Cologne consensus conference on pulmonary hypertension â€“ Update 2018. International Journal of Cardiology, 2018, 272, 1-3.	1.7	10
206	Debating the new haemodynamic definition of pulmonary hypertension: much ado about nothing?. European Respiratory Journal, 2019, 54, 1901278.	6.7	10
207	The pulmonary haemodynamics during exercise â€“ research network (PEX-NET) ERS Clinical Research Collaboration: investigating the prognostic relevance ofÂexercise haemodynamics. European Respiratory Journal, 2019, 53, 1900458.	6.7	10
208	Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension. Respiration, 2007, 74, 498-502.	2.6	9
209	The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma. British Journal of Clinical Pharmacology, 2010, 69, 271-278.	2.4	9
210	Borderline pulmonary pressures in scleroderma - a â€˜pre-pulmonary arterial hypertensionâ€™ condition?. Arthritis Research and Therapy, 2015, 17, 123.	3.5	9
211	Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: An in vitro study. Neuroscience Research, 2016, 109, 16-27.	1.9	9
212	Whole-Body Lung Function Testâ€“Derived Outcome Predictors in Allogenic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 129-136.	2.0	9
213	PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension. Journal of Rheumatology, 2013, 40, 1777-1779.	2.0	8
214	No erythropoietin-induced growth is observed in non-small cell lung cancer cells. International Journal of Oncology, 2017, 52, 518-526.	3.3	8
215	Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L59-L73.	2.9	7
216	Pulmonary arterial pressure in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2016, 57, 2723-2726.	1.3	7

#	Article	IF	Citations
217	Sleep Related Breathing Disorders and Inflammation â€" The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment. PLoS ONE, 2015, 10, e0137594.	2.5	7
218	Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation. Biomolecules, 2021, 11, 1629.	4.0	7
219	Letter by Olschewski et al Regarding Article, â€œUpregulation of K _{2P} 3.1 K ⁺ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillationâ€. Circulation, 2016, 133, e439.	1.6	6
220	Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report. BMC Medical Imaging, 2016, 16, 45.	2.7	6
221	External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer. Annals of Oncology, 2019, 30, v514.	1.2	6
222	Automated vortical blood flow-based estimation of mean pulmonary arterial pressure from 4D flow MRI. Magnetic Resonance Imaging, 2022, 88, 132-141.	1.8	6
223	AMBRISENTAN RESCUE THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION WHO DISCONTINUED BOSENTAN OR SITAXSENTAN DUE TO LIVER FUNCTION ABNORMALITIES. Chest, 2006, 130, 254S.	0.8	5
224	Does exercise pulmonary hypertension exist?. Current Opinion in Pulmonary Medicine, 2016, 22, 400-407.	2.6	5
225	Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 870-882.	5.7	5
226	The definition of pulmonary hypertension: history, practical implications and current controversies. Breathe, 2021, 17, 210076.	1.3	5
227	Prostacyclins. Handbook of Experimental Pharmacology, 2013, 218, 177-198.	1.8	5
228	Pulmonary Lobe Segmentation in CT Images using Alpha-Expansion. , 2018, , .		5
229	Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy. European Respiratory Journal, 2014, 43, 1513-1515.	6.7	4
230	Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?. Respiration, 2015, 89, 513-514.	2.6	4
231	Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia. Frontiers in Physiology, 2017, 8, 98.	2.8	4
232	TMEM16A Potentiation: Possible Drawbacks. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 904-905.	5.6	4
233	Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry. Respiration, 2016, 91, 26-33.	2.6	3
234	Pulmonary and cardiac drugs: clinically relevant interactions. Herz, 2019, 44, 517-521.	1.1	3

#	Article	IF	Citations
235	Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2019, 4, 219-224.	1.7	3
236	Imatinib for right heart failure in COPD. Pulmonary Circulation, 2019, 9, 1-3.	1.7	3
237	Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. BMC Pulmonary Medicine, 2021, 21, 13.	2.0	3
238	Pulmonary Hypertension May Be a Relevant Comorbidity in Patients with Myelodysplastic Syndromes. Blood, 2011, 118, 5039-5039.	1.4	3
239	Monocytes and Macrophages Serve as Potent Prostaglandin D2 Sources during Acute, Non-Allergic Pulmonary Inflammation. International Journal of Molecular Sciences, 2021, 22, 11697.	4.1	3
240	Long Term Use Of Imatinib In Patients With Severe Pulmonary Arterial Hypertension. , 2010, , .		2
241	A 57-Year-Old Woman With Obesity, Respiratory Insufficiency, and Slowed Mental State. Chest, 2013, 144, 347-348.	0.8	2
242	Pulmonary capillary recruitment in exercise and pulmonary hypertension. European Respiratory Journal, 2018, 51, 1800260.	6.7	2
243	RGS5 Determines Neutrophil Migration in the Acute Inflammatory Phase of Bleomycin-Induced Lung Injury. International Journal of Molecular Sciences, 2021, 22, 9342.	4.1	2
244	Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension. Advances in Pulmonary Hypertension, 2002, 1, 16-21.	0.1	2
245	IMATINIB MESYLATE TREATMENT FOR SEVERE PULMONARY ARTERIAL HYPERTENSION: A PROPOSED PHASE III 24-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED CLINICAL TRIAL. Chest, 2009, 136, 64S.	0.8	1
246	Pirfenidone and N-acetylcysteine (NAC) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF): Exploratory Efficacy Results From the PANORAMA Study. Chest, 2015, 148, 641A.	0.8	1
247	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2018, 130, 581-588.	1.9	1
248	Should patients with pulmonary hypertension fly and climb?. International Journal of Cardiology, 2018, 270, 276-277.	1.7	1
249	Advanced interstitial lung fibrosis with emphysema and pulmonary hypertension with no evidence for interstitial lung disease on high resolution CT. Pulmonary Circulation, 2019, 9, 204589401983221.	1.7	1
250	Normalized Vessel Volume from Quantitative Computed Tomography Predicts Survival in Idiopathic Pulmonary Fibrosis. , 2019, , .		1
251	No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity. European Respiratory Journal, 2020, 55, 1901228.	6.7	1
252	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2021, 133, 65-72.	1.9	1

#	Article	IF	Citations
253	Impact of Smoking Behavior on Survival Following Allogeneic Hematopoietic Stem Cell Transplantation â€“ Smoking Cessation Matters. Nicotine and Tobacco Research, 2021, 23, 1708-1715.	2.6	1
254	Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer. Wiener Klinische Wochenschrift, 2021, 133, 1122-1130.	1.9	1
255	Right ventricular tissue doppler echocardiography in pulmonary hypertension. , 2018, , .		1
256	Does brain natriuretic peptide (BNP) at baseline influence the effects of nintedanib plus sildenafil in patients with IPF?. , 2019, , .		1
257	Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis. , 2019, , .		1
258	Exercise in Pulmonary Hypertension. Advances in Pulmonary Hypertension, 2012, 10, 237-240.	0.1	1
259	Automatic Artery-Vein Separation from Thoracic CT Images Using Integer Programming. Lecture Notes in Computer Science, 2015, , 36-43.	1.3	1
260	Pulmonary hypertension in hypersensitivity pneumonitis. , 2016, , .		1
261	Transcriptome profiling reveals the complexity of pirfenidone effects in IPF. , 2019, , .		1
262	Utility of D-Dimer for mortality prediction in patients at risk for pulmonary hypertension. , 2020, , .		1
263	Circulating microRNAs as molecular biomarkers for lung adenocarcinoma. Cancer Biomarkers, 2022, , 1-16.	1.7	1
264	Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022). Wiener Klinische Wochenschrift, 2022, 134, 399-419.	1.9	1
265	Potassium Channels in the Transition from Fetal to the Neonatal Pulmonary Circulation. International Journal of Molecular Sciences, 2022, 23, 4681.	4.1	1
266	SCREENING FOR PULMONARY ARTERIAL HYPERTENSION WITH EXERCISE-STRESS-ECHOCARDIOGRAPHY AND CARDIOPULMONARY EXERCISE TESTING. Chest, 2007, 132, 622A.	0.8	0
267	Should Patients With Connective Tissue Disease Undergo Exercise Doppler Echocardiography?: Response. Chest, 2010, 138, 1524.	0.8	0
268	Bronchiolitis Obliterans In Allogeneic Haematopoietic Stem Cell Transplantation Following Nonmyeloablative Conditioning. , 2010, , .		0
269	Early Therapy With Bosentan Reverses Progressing Pulmonary Vasculopathy In Scleroderma Patients. , 2010, , .		0
270	Why We Should Care about the Mysteries of Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 249-250.	1.7	0

#	Article	IF	Citations
271	Understanding exercise hemodynamics. Pulmonary Circulation, 2017, 7, 565-566.	1.7	0
272	Advancing into the details of pulmonary haemodynamics during exercise. European Respiratory Journal, 2018, 52, 1801578.	6.7	0
273	Take your drug and climb Machu Picchu!. International Journal of Cardiology, 2019, 288, 135-136.	1.7	0
274	THU0340â€…IMPACT OF LANIFIBRANOR, A PAN-PPAR AGONIST, ON THE PULMONARY VASCULAR TONE. , 2019, , .		0
275	The Effect of Nintedanib on Pulmonary Vascular Tone in an Experimental Model of Lung Fibrosis and Pulmonary Hypertension. , 2019, , .		0
276	P62.08 Expression Pattern and Prognostic Significance of Gluconeogenesis Enzymes in Lung Cancer.. Journal of Thoracic Oncology, 2021, 16, S550.	1.1	0
277	Erfolgreiche Behandlung einer schweren interstitiellen Pneumonie durch Entfernung zirkulierender AutoantikÃ¶rper: eine Fallserie. Karger Kompass Pneumologie, 2021, , 96-101.	0.0	0
278	Correction: Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2006, 144, 863.	3.9	0
279	Prostacyclin and Prostaglandins. , 2011, , 1451-1463.		0
280	The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines. , 2015, , .		0
281	Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension. , 2015, , .		0
282	LATE-BREAKING ABSTRACT: Safety and tolerability of N-acetylcysteine (NAC) with pirfenidone in idiopathic pulmonary fibrosis (IPF): PANORAMA. , 2015, , .		0
283	Pulmonale Hypertonie. , 2016, , 313-329.		0
284	LATE-BREAKING ABSTRACT: Impact of NSAIDs on success of chemical pleurodesis in malignant pleural effusion. , 2016, , .		0
285	Progression of Lung Cancer: Role of Hypoxia and the Metabolic Tumor Microenvironment. , 2017, , 287-299.		0
286	Screening for pulmonary vascular disease (PVD) in patients with portal hypertension by investigating pulmonary hemodynamics during exercise. , 2017, , .		0
287	Validation of cardiac MR parameters in the assessment of pulmonary hemodynamics. , 2017, , .		0
288	Eosinophilic inflammation and worsening of lung function upon pirfenidone treatment in Fra-2 transgenic mice. , 2018, , .		0

#	Article	IF	Citations
289	Pulmonary hypertension in hypersensitivity pneumonitis.. , 2018, , .		0
290	Impact of diastolic dysfunction on exercise capacity in patients with liver cirrhosis. , 2018, , .		0
291	Pulmonary vascular disease (PVD) in patients with SjÃ¶gren syndrome - a prospective cross-sectional study. , 2019, , .		0
292	Discordant perception of global health between COPD outpatients and their physicians â€“ real world data from the CLARA project. , 2020, , .		0
293	Exercise Pulmonary Vascular Resistances are Predictors of Survival in Systemic Sclerosis. , 2020, , .		0
294	MPAP/CO-slope during exercise as predictor of mortality in patients at risk for pulmonary hypertension. , 2020, , .		0
295	Pulmonary exercise hemodynamics in patients with liver cirrhosis â€“ a stress echocardiography study. , 2020, , .		0
296	The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis. , 2020, , .		0
297	Impact of the new definition of precapillary pulmonary hypertension on patient disposition. , 2020, , .		0
298	Basement membrane, a specialized extracellular matrix, shapes endothelial function in IPAH. , 2020, , .		0
299	Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial. , 2020, , .		0
300	Pulmonary Vascular Resistances are Predictors of 3-year-survival in Systemic Sclerosis. , 2020, , .		0
301	Lung vessel morphology changes with airway obstruction. , 2020, , .		0
302	Exercise hemodynamics in patients with COPD. , 2020, , .		0